COST-EFFECTIVENESS ANALYSIS OF RIVAROXABAN VERSUS DABIGATRAN AND ENOXAPARIN FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM AFTER TOTAL KNEE REPLACEMENT

被引：0
|
作者：
Vorobyev, P. [1 ]
Krasnova, L. [2 ]
Borisenko, O. [1 ]
Lukyantseva, D. [2 ]
Bashlakova, L. [2 ]
机构：
[1] Russian Soc Pharmacoecon & Outcomes Res, Moscow, Russia
[2] Moscow State Med Univ, Moscow, Russia
来源：
VALUE IN HEALTH | 2011年 / 14卷 / 03期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A41 / A41
页数：1
相关论文
共 50 条
  • [41] Cost-Effectiveness of Different Strategies for the Prevention of Venous Thromboembolism After Total Hip Replacement in China
    Yan, Xiaoyu
    Gu, Xiaohua
    Xu, Zhenxing
    Lin, Houweng
    Wu, Bin
    ADVANCES IN THERAPY, 2017, 34 (02) : 466 - 480
  • [42] COST-EFFECTIVENESS ANALYSIS OF BEMIPARIN AS PROPHYLAXIS FOR VENOUS THROMBOEMBOLISM IN TOTAL KNEE REPLACEMENT SURGERY IN MEXICO
    Carlos, F.
    Aguirre, A.
    Esquivel, R.
    Nettel, J.
    Meillon, L.
    Bierschwale, H.
    VALUE IN HEALTH, 2012, 15 (07) : A445 - A445
  • [43] COST-EFFECTIVENESS OF RIVAROXABAN VERSUS DABIGATRAN FOR THROMOBOPROPHYLAXIS IN TOTAL HIP REPLACEMENT SURGERY IN THE UNITED STATES
    Raval, A.
    Vyas, A.
    Kamal, K.
    VALUE IN HEALTH, 2014, 17 (03) : A116 - A116
  • [44] Rivaroxaban Versus Enoxaparin for Venous Thromboembolism Prophylaxis after Hip and Knee Arthroplasty
    Charters, Michael A.
    Frisch, Nicholas B.
    Wessell, Nolan M.
    Dobson, Christopher
    Les, Clifford M.
    Silverton, Craig D.
    JOURNAL OF ARTHROPLASTY, 2015, 30 (07): : 1277 - 1280
  • [45] Cost-effectiveness of dabigatran etexilate in Canada for the primary prevention of venous thromboembolism in patients undergoing total hip replacement surgery
    Bradley-Kennedy, C.
    Wolowacz, S. E.
    Roskell, N. S.
    Plumb, J. M.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 786 - 786
  • [46] COST-EFFECTIVENESS ANALYSIS OF ENOXAPARIN FOR EXTENDED THROMBOPROPHYLAXIS OF VENOUS THROMBOEMBOLISM (VTE) AFTER ELECTIVE TOTAL HIP REPLACEMENT (THR) SURGERY
    Weitz, J.
    Bernard, L.
    Wakeford, C.
    VALUE IN HEALTH, 2009, 12 (07) : A333 - A333
  • [47] Oral Dabigatran Etexilate Versus Enoxaparin for Prevention of Venous Thromboembolism After Total Hip or Knee Arthroplasty: A Pooled Analysis of Four Randomized Trials
    Huo, Michael H.
    Kurth, Andreas A.
    Dahl, Ola E.
    Clemens, Andreas
    Hantel, Stefan
    Feuring, Martin
    Friedman, Richard J.
    Eriksson, Bengt I.
    BLOOD, 2011, 118 (21) : 1002 - 1002
  • [48] Cost-effectiveness of rivaroxaban versus warfarin anticoagulation for the prevention of recurrent venous thromboembolism: A US perspective
    Seaman, Craig D.
    Smith, Kenneth J.
    Ragni, Margaret V.
    THROMBOSIS RESEARCH, 2013, 132 (06) : 647 - 651
  • [49] Direct factor Xa inhibitors (rivaroxaban and apixaban) versus enoxaparin for the prevention of venous thromboembolism after total knee replacement: A meta-analysis of 6 randomized clinical trials
    Ma, Guofeng
    Zhang, Ruifeng
    Wu, Xiaohong
    Wang, Dan
    Ying, Kejing
    THROMBOSIS RESEARCH, 2015, 135 (05) : 816 - 822
  • [50] COST ANALYSIS OF VENOUS THROMBOEMBOLISM PROPHYLAXIS AFTER TOTAL KNEE REPLACEMENT AND TOTAL HIP REPLACEMENT
    Marmarali, B.
    Altintas, F.
    Bal, K.
    Bozkurt, K.
    Demir, M.
    Erdemli, B.
    Ince, B.
    Ongen, G.
    Deger, C.
    Parali, E.
    Saka, G.
    Koksal, T.
    Yuvakuran, M.
    VALUE IN HEALTH, 2012, 15 (04) : A119 - A119
12345